Premium
Serum 5‐S‐Cysteinyldopa (5‐S‐CD) as a Marker of Melanoma Progression
Author(s) -
Horikoshi Takashi,
Ito Shosuke
Publication year - 1992
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1992.tb03787.x
Subject(s) - melanoma , urine , medicine , urinary system , stage (stratigraphy) , melanin , tumor marker , excretion , disease , metastasis , serum concentration , tumor progression , cancer , pathology , gastroenterology , cancer research , biology , paleontology , genetics
We previously reported that serum 5‐S‐cysteinyldopa (5‐S‐CD) tended to elevate earlier and reflect melanoma progression better than urinary 5‐S‐CD. In patients without metastatic melanomas, serum concentration and urinary excretion of 5‐S‐CD and 6‐hydroxy‐5‐methoxyindole‐2‐carboxylic acid (6H5MI2C) were within the upper limits of normal controls. In this report, we presented more precisely the changes in these melanin‐related markers and clinical courses of four melanoma patients. Serum and 24‐hour urine samples were serially collected and assayed every 1 to 4 months. Three of them developed stage IV malignant melanomas and died of metastatic disease. 6H5MI2C in serum and urine did not reflect the progression of disease. Among the 4 parameters considered, 5‐S‐CD in serum appeared to be the best biochemical marker for melanoma progression. Serum 5‐S‐CD over the upper limit of 10 nmol/L was suggested as a serious sign of the progression of melanoma.